Key Drivers
- Cash conversion
- Thin liquidity
- Heavy leverage
AIAI Summary
FMS is now best viewed as an execution-and-remediation story rather than a pure growth play: operations and cash flow are improving, but the investment case hinges on proving that FME25+ savings and U.S. network restructuring can offset transformation costs and turn flat 2026 guidance into durable margin expansion.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash conversion
- •Thin liquidity
- •Heavy leverage
FMS looks fairly inexpensive and cash-generative with solid annual earnings quality, but elevated leverage, thin liquidity, and weaker quarterly cash flow temper the outlook.
Price Behavior
Key Price Behavior Insights:
- •Weak rebound
- •Overhead resistance
- •Support holding
Over the last month, FMS stayed in a short-term downtrend, rebounded off $20.19 to the low $21s, but remains capped by $22.24-$22.65, leaving the setup neutral-to-bearish unless it holds $21.00 and breaks resistance.
Sharp rebound from $20.19 on 2026-05-05 to the low $21s, then faded back to $21.60
Sentiment & News
Key News Insights:
- •Margin expansion
- •U.S. restructuring
- •Undervalued shares
Fresenius Medical Care delivered solid Q1 organic growth and margin expansion with guidance intact, while one-time transformation costs, U.S. clinic exits, and FX/divestitures weighed on reported results as investors focused on savings progress and cheap valuation.
The update is mildly positive for the stock because operational improvements and cost savings appear to be outweighing near-term reported earnings pressure
Similar Companies in Healthcare
Other companies in the same sector with AI ratings